Table 1.
Characteristics of the 6 studies included in the meta-analysis
| Study | Region | Study type | Interventions | Sample size | Agea (years) | Gender (F/M) | Follow-up period |
|---|---|---|---|---|---|---|---|
| Koklu et al. (2015) [16] | Turkey | Case control | LAM/ETV/TDF | LAM: 302 | LAM: 49.21 ± 13.17 | 292/565 | 2 years |
| ETV: 282 | ETV: 49.86 ± 13.35 | ||||||
| TDF: 273 | TDF: 47.74 ± 12.45 | ||||||
| Lee et al. (2015) [19] | Korea | Cohort | LdT/ETV | LdT: 116 | LdT: 53.6 ± 10.9 | 229/465 | 1.5 years |
| ETV: 578 | ETV: 54.8 ± 11.3 | ||||||
| Jia et al. (2015) [15] | China | Cohort | ADV/ETV | ADV: 165 | ADV: 46.2 ± 9.2 | 95/235 | 5 years |
| ETV: 165 | ETV: 48.6 ± 8.7 | ||||||
| Liang et al. (2014) [20] | Taiwan | Cohort | LdT/ETV | LdT: 34 | LdT: 46.68 ± 1.87 | 10/44 | 1 year |
| ETV: 20 | ETV: 44.45 ± 1.95 | ||||||
| Yan & Han (2012) [21] | China | RCT | LdT/ETV/ADV | LdT: 50 | LdT: 37.3 (22-59) | 36/79 | 1 years |
| ETV: 35 | ETV: 43.0 (21-64) | ||||||
| ADV: 30 | ADV: 39.4 (25-62) | ||||||
| Gane et al. (2013) [9] | Worldwide | RCT | LdT/LAM | LdT: 680 | N/A | N/A | 2 years |
| LAM: 687 |
aAge expressed as mean ± SD or median (range)
ADV adefovir, ETV entecavir, LAM lamivudine, LdT telbivudine, N/A not applicable, RCT randomized controlled trial, TDF tenofovir